Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study demonstrated a statistically significant improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Key secondary endpoints, such as progression-free survival (PFS) and overall response rate (ORR), also showed positive outcomes. The safety profile of ADCETRIS aligned with previous findings. The full data is set for presentation at an upcoming medical meeting.
ADCETRIS, an antibody-drug conjugate, targets CD30 and has become a care standard for certain lymphomas. It is approved for seven indications in the U.S, serving over 55,000 patients since 2011 and globally treating more than 140,000 patients.
The ECHELON-3 trial, international in scope, explored ADCETRIS plus lenalidomide and rituximab against lenalidomide and rituximab with placebo in patients having received two or more lines of therapy who were ineligible for stem cell transplant or CAR-T therapy. The primary outcome focused on OS, with PFS and ORR as secondary endpoints.
DLBCL, the most common lymphoma type, presents significant treatment challenges with up to 40% of patients experiencing relapse or refractory disease post-first-line treatment. Pfizer intends to discuss the ECHELON-3 data with the FDA to support regulatory filings in the U.S.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
